Eur Rev Med Pharmacol Sci 2019; 23 (24): 10678-10684
DOI: 10.26355/eurrev_201912_19766

Long noncoding RNA TTN-AS1 promotes the proliferation and migration of prostate cancer by inhibiting miR-1271 level

Y. Zhu, Z. Yang, X.-H. Luo, P. Xu

Department of Radiation Oncology, Baoji Central Hospital, Baoji, China. xuping198008@163.com


OBJECTIVE: Prostate cancer is one of the most common malignant tumors. Recently, the role of long noncoding RNAs (lncRNAs) in tumor progression has been well concerned by numerous researchers. In this research, lncRNA TTN-AS1 was studied to identify its biological function in the progression of prostate cancer.
PATIENTS AND METHODS: Firstly, Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was conducted to measure TTN-AS1 expression in prostate cancer tissues. Furthermore, in vitro role of TTN-AS1 in regulating prostate cancer cells was assessed. Tumor formation assay was conducted in NOD/SCID mice to explore the in vitro function of TTN-AS1. In addition, the luciferase reporter gene assay was performed to analyze the relationship between TTN-AS1 and miR-1271.
RESULTS: TTN-AS1 expression was remarkably higher in prostate cancer samples compared with that of corresponding ones. Moreover, proliferation and migration of prostate cancer cells were inhibited after TTN-AS1 was silenced. MiR-1271 was upregulated after the silence of TTN-AS1. Further mechanism assays showed that miR-1271 was a direct target of TTN-AS1 in prostate cancer. In addition, tumor formation and metastasis abilities were inhibited after in vivo knockdown of TTN-AS1.
CONCLUSIONS: Our study discovers a potential oncogene in prostate cancer and demonstrates that TTN-AS1 enhances cell proliferation and migration via sponging miR-1271.

This article has been withdrawn. The Publisher apologizes for any inconvenience this may cause.

Free PDF Download

To cite this article

Y. Zhu, Z. Yang, X.-H. Luo, P. Xu
Long noncoding RNA TTN-AS1 promotes the proliferation and migration of prostate cancer by inhibiting miR-1271 level

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 24
Pages: 10678-10684
DOI: 10.26355/eurrev_201912_19766